Aclarion announces clarity trial for nociscan now fully funded

The company has secured nearly $20 million in gross proceeds in 2025 ensuring complete funding for its pivotal clarity trial clarity is a prospective, randomized, multicenter study to validate nociscan's ability to improve surgical outcomes nociscan aims to become the gold standard in identifying sources of low back pain through mr spectroscopy (mrs) and augmented intelligence (ai) broomfield, colo., feb. 04, 2025 (globe newswire) -- aclarion, inc., (“aclarion” or the “company”) (nasdaq: acon, aconw), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (ai) algorithms to help physicians identify the location of chronic low back pain, announced today that it has secured full funding for its pivotal clarity trial which is designed to demonstrate nociscan's clinical and economic value in spine surgery.
ACON Ratings Summary
ACON Quant Ranking